Key takeaways from the Fall 2025 AARR meeting are presented, which brought together academic, clinical, and industry leaders to discuss and explore the current advances in the heterogeneity and co‐pathologies of AD and their implications for diagnosis, clinical trial design, and precision treatment strategies.
M. Tansey, S. Bozeat, Peter Ackerman et al.· Alzheimer's & Dementia· 0 citations
GenFAR, a modular deep learning framework that learns general, clinically informed features from brain MRIs, is introduced, showing that using the learned feature representation can substantially increase the sample efficiency of secondary deep learning training tasks and models, as well as improve their accuracy.
V. Bashyam, G. Erus, Jun-Hao Wen et al.· 0 citations
Leveraging multi-omics to better understand the molecular signatures and pathways underlying Alzheimer’s disease (AD) pathogenesis is critical for early diagnosis and disease modifying interventions. We performed peripheral blood transcriptome (N = 669) and epigenome microarray analyses (N = 553) on non-Hispanic white...
Brendan A. Mitchell, I. Hausle, Sarah Smith et al.· npj Dementia· 0 citations
While most studies of Alzheimer's disease (AD) examine cross‐sectional relationships among biomarkers, longitudinal relationships are also highly relevant.
B. Saef, K. K. Petersen, Katherine E. Volluz et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
